[Form 4] Veracyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Veracyte insider Phillip G. Febbo reported a non-sale disposition of 2,955 shares of common stock on 09/02/2025. The transaction reflects shares withheld to satisfy tax withholding obligations related to the vesting of restricted stock units, executed at a reported price of $30.11 per share. After the withholding, the reporting person beneficially owns 100,790 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and identifies Febbo as the company’s Chief Scientific & Medical Officer and an officer of Veracyte (VCYT).

Positive

• Beneficial ownership retained: Reporting person still holds 100,790 shares after withholding
• Transaction disclosed as non-sale tax withholding related to RSU vesting, clarifying it was not an active market sale

Negative

• Shares reduced by 2,955 due to tax withholding for vested restricted stock units
• Withholding valued at $30.11 per share, which reduced the reporting person's outstanding share count

Insights

Securities Insider Transactions Analyst

TL;DR: Routine tax-withholding disposition from RSU vesting; not a market sale.

This Form 4 documents a withholding of 2,955 shares to cover tax obligations when restricted stock units vested. The filing is a non-sale disposition coded as F(1) and reports a per-share withholding valuation of $30.11. The resulting beneficial ownership of 100,790 shares remains intact. For investors, this is a routine administrative action by an executive and does not indicate active selling or a change in control.

Corporate Governance / Compensation Specialist

TL;DR: Compensation-related share withholding; highlights RSU-based pay practices.

The Form 4 clarifies that the transaction arose from RSU vesting and tax withholding rather than a voluntary market sale, consistent with standard executive compensation settlement. The record shows the reporting person’s role as Chief Scientific & Medical Officer, confirming alignment between recorded equity awards and executive compensation mechanisms. This disclosure meets Section 16 reporting requirements and provides transparency on share count changes due to compensation events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Febbo Phillip G.

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Med Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F(1)		2,955	D	$30.11	100,790	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Phillip G. Febbo report on Form 4 for Veracyte (VCYT)?

He reported a non-sale disposition of 2,955 shares on 09/02/2025 due to tax withholding from RSU vesting.

Was the Form 4 transaction a sale of Veracyte (VCYT) stock?

No. The filing states the shares were withheld to satisfy tax withholding obligations and explicitly notes this does not represent a sale.

How many Veracyte (VCYT) shares does the reporting person beneficially own after the transaction?

The Form 4 reports 100,790 shares beneficially owned following the withholding.

What price was used for the withheld shares in the Form 4?

The withheld shares are reported at a price of $30.11 per share.

What is Phillip Febbo’s role at Veracyte as listed on the filing?

He is listed as an Officer, specifically the Chief Scientific & Medical Officer.